septerna - Search News

News

Novo Nordisk Inks $2.2B Deal With Septerna

The Wall Street Journal on MSN · 10h

Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases.

Contract Pharma · 50m

Novo Nordisk Invests $2.2B in Septerna’s Oral Drugs

Septerna, Novo Nordisk partner to discover, develop and commercialize oral small molecule medicines for cardiometabolic diseases.

Reuters on MSN · 1d

Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that could be worth up to $2.

1d

Novo Nordisk, Septerna sign $2.2B deal to develop weight-loss pill

Pharmaceutical giant Novo Nordisk (NVO) inks a $2.2 billion deal with biotech company Septerna (SEPN) to develop a GLP-1 ...

Novo Nordisk strikes deal with Septerna to develop obesity pills

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results